MicroRNA在子宫内膜癌发生、发展及临床诊治中的研究  

Research of endometrial cancer occurrence,development,clinical diagnosis and treatment-related microRNA

作　　者：王淑芳[1] 冯玉珍[1] 霍新龙[2] 

机构地区：[1]河北医科大学第三医院妇产科,河北石家庄050051 [2]河北省秦皇岛市第一医院肿瘤科,河北秦皇岛066000

出　　处：《中国医药导报》2013年第6期30-32,共3页China Medical Herald

基　　金：国家自然基金资助项目(项目编号:30772317)

摘　　要：microRNA是一种内源性的大小在20 nt左右的一类非编码RNAs,其通过下调靶基因的表达或翻译而参与调节细胞的发育、增殖、分化、凋亡。近期研究发现microRNA具有癌基因和抑癌基因的作用,已发现miR-21,miR-200c,miR-205,MiR-125b,miR-194等与子宫内膜癌的发生、发展、侵袭及转移相关,miRNA-200家族则参与子宫内膜癌的耐药机制。对其相应的调控机制和靶基因PTEN,TP53INP1,BMI-1,AP-2α等的研究也已有了一些进展,为子宫内膜癌的研究开辟了一条新途径。本文就子宫内膜癌相关Micro RNA的研究进展予以综述。microRNA are endogenous non-coding RNAs about 20 nt that can play important regulatory roles in de- velopment,proliferation, diferentiation and apoptosis with respect to cells by negatively controlling expression or trans- lation on target mRNA. Recent studies indicate that microRNA can function as both oncogene and anti-oncogene. miR-21, miR-200c, miR-205, MiR-125b, miR-194 etc, have been demonstrated to be related with tumorigenesis, de- velopment, invasiveness and metastasis, while miR-200 are regarded to be correlated with multidrug resistance in en- dometrial cancer. There are already much advancement in research of the regulatory mechanism and target genes, as PTEN, TP53INP1, BMI-1, AP-2ct and so forth, which might provide a new way in studying endometrial cancer. This article reviewed the research advancement about microRNA in endometrial cancer.

关 键 词：MICRORNA 子宫内膜癌 癌基因 抑癌基因 肿瘤 

分 类 号：R737.33[医药卫生—肿瘤]